Should the patent system for new medicines be abolished?
DiMasi
J A
JA
Tufts Center for the Study of Drug Development, Tufts University, Boston, Massachusetts, USA.
Grabowski
H G
HG
D035843:Biomedical Research / Q000331:legislation & jurisprudence*; D003132:Commerce / Q000331:legislation & jurisprudence*; D003362:Cost-Benefit Analysis; D016527:Drug Costs / Q000331:legislation & jurisprudence*; D004345:Drug Industry / Q000331:legislation & jurisprudence*; D005380:Financing, Government; D006801:Humans; D019458:Insurance Coverage; D007880:Legislation, Drug / Q000592:standards* / Q000639:trends; D009965:Orphan Drug Production / Q000331:legislation & jurisprudence; D010330:Patents as Topic / Q000331:legislation & jurisprudence*; D004364:Pharmaceutical Preparations / Q000191:economics*; D011640:Public Policy; D014481:United States
D004364:Pharmaceutical Preparations